<!doctype html><html><head><title>AL Amyloidosis</title><base href="../"><meta id="root-path" root-path="../"><link rel="icon" sizes="96x96" href="https://publish-01.obsidian.md/access/f786db9fac45774fa4f0d8112e232d67/favicon-96x96.png"><meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=yes,minimum-scale=1,maximum-scale=5"><meta charset="UTF-8"><link rel="stylesheet" href="lib/styles/obsidian-styles.css"><link rel="stylesheet" href="lib/styles/theme.css"><link rel="stylesheet" href="lib/styles/plugin-styles.css"><link rel="stylesheet" href="lib/styles/snippets.css"><link rel="stylesheet" href="lib/styles/generated-styles.css"><style></style><script type="module" src="lib/scripts/graph_view.js"></script><script src="lib/scripts/graph_wasm.js"></script><script src="lib/scripts/tinycolor.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/pixi.js/7.2.4/pixi.min.js" integrity="sha512-Ch/O6kL8BqUwAfCF7Ie5SX1Hin+BJgYH4pNjRqXdTEqMsis1TUYg+j6nnI9uduPjGaj7DN4UKCZgpvoExt6dkw==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><script src="lib/scripts/webpage.js"></script><script src="lib/scripts/generated.js"></script></head><body class="theme-light show-inline-title loading"><div class="webpage-container"><div class="sidebar-left sidebar"><div class="sidebar-container"><div class="sidebar-sizer"><div class="sidebar-content-positioner"><div class="sidebar-content"><div><label class="theme-toggle-container" for="theme_toggle"><input class="theme-toggle-input" type="checkbox" id="theme_toggle"><div class="toggle-background"></div></label></div><div class="tree-container file-tree mod-nav-indicator" data-depth="0"><div class="tree-header"><span class="sidebar-section-header">Notes</span><button class="clickable-icon collapse-tree-button is-collapsed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></svg></button></div><div class="tree-scroll-area"><div class="tree-item mod-tree-folder mod-collapsible is-collapsed" data-depth="1"><div class="tree-item-contents"><a class="internal-link tree-item-link"><div class="tree-item-icon collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle"><path d="M3 8L12 17L21 8"></path></svg></div><span class="tree-item-title">Blog</span></a></div><div class="tree-item-children" style="display:none"><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="blog/sample-1.html"><span class="tree-item-title">Sample 1</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="blog/sample-2.html"><span class="tree-item-title">Sample 2</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="blog/sample-3.html"><span class="tree-item-title">Sample 3</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="blog/sample-4.html"><span class="tree-item-title">Sample 4</span></a></div><div class="tree-item-children"></div></div></div></div><div class="tree-item mod-tree-folder mod-collapsible is-collapsed" data-depth="1"><div class="tree-item-contents"><a class="internal-link tree-item-link"><div class="tree-item-icon collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle"><path d="M3 8L12 17L21 8"></path></svg></div><span class="tree-item-title">Plasma Cell Disorders</span></a></div><div class="tree-item-children" style="display:none"><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/active-multiple-myeloma.html"><span class="tree-item-title">Active Multiple Myeloma</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/al-amyloidosis.html"><span class="tree-item-title">AL Amyloidosis</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/amyloidosis-nejm.html"><span class="tree-item-title">Amyloidosis NEJM</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/amyloidosis_-general.html"><span class="tree-item-title">Amyloidosis_ general</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/mgus-monoclonal-gammopathy-of-undetermined-signi.html"><span class="tree-item-title">MGUS - Monoclonal Gammopathy of Undetermined Signi</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/monoclonal-gammopathy-disorders-(fellow).html"><span class="tree-item-title">Monoclonal Gammopathy Disorders (Fellow)</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/myeloma-canvas.html"><span class="tree-item-title">Myeloma Canvas</span></a></div><div class="tree-item-children"></div></div></div></div></div></div></div></div></div></div><div class="sidebar-gutter"><div class="clickable-icon sidebar-collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><path d="M21 3H3C1.89543 3 1 3.89543 1 5V19C1 20.1046 1.89543 21 3 21H21C22.1046 21 23 20.1046 23 19V5C23 3.89543 22.1046 3 21 3Z"></path><path d="M10 4V20"></path><path d="M4 7H7"></path><path d="M4 10H7"></path><path d="M4 13H7"></path></svg></div></div></div><div class="document-container show"><div class="markdown-preview-view markdown-rendered node-insert-event allow-fold-headings show-indentation-guide allow-fold-lists show-properties" style="tab-size:4"><style id="MJX-CHTML-styles"></style><div class="markdown-preview-sizer markdown-preview-section" style="min-height:198px"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"><div class="inline-title" data-heading="AL Amyloidosis" id="AL_Amyloidosis" style="display:block">AL Amyloidosis</div></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> AL amyloidosis
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2022-07-25 03:19:18Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2021-05-21 17:46:35Z</span></code><button class="copy-code-button">Copy</button></pre></div><div><p>Epidemiology</p></div><div><p><span width="475" alt="WhatsApp Image 2023-06-23 at 13.11.07.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.11.07.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.11.07.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.11.07.jpg" style="max-width:100%"></span></p></div><div><p><strong>Most common forms of systemic amyloidosis</strong></p></div><div><p>AL amyloidosis may co-occur with multiple myeloma approximately 10% of the time</p></div><div><p>The plasma cell clone in AL amyloidosis is typically smaller and not as proliferative as in myeloma;</p></div><div><p>these clonal cells secrete light chains predominantly (but not exclusively) of the lambda type.</p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.08.39.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.39.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.08.39.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.39.jpg" style="max-width:100%"></span></p></div><div><p><span width="450" alt="WhatsApp Image 2023-06-23 at 13.13.25.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.13.25.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.13.25.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.13.25.jpg" style="max-width:100%"></span></p></div><div><p>Pathophysiology</p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.16.20.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.16.20.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.16.20.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.16.20.jpg" style="max-width:100%"></span></p></div><div><p></p><div width="600" alt="../_resources/bf80dd8f4263b9d0c0ce6b04043f9ad0.png" src="lib\media\bf80dd8f4263b9d0c0ce6b04043f9ad0.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/bf80dd8f4263b9d0c0ce6b04043f9ad0.png" src="lib\media\bf80dd8f4263b9d0c0ce6b04043f9ad0.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/43bbb381ae4337f39ec30708df86ea3f.png" src="lib\media\43bbb381ae4337f39ec30708df86ea3f.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/43bbb381ae4337f39ec30708df86ea3f.png" src="lib\media\43bbb381ae4337f39ec30708df86ea3f.png" style="max-width:100%"></div><p></p></div><div><p><strong>Symptoms of amyloidosis&nbsp;</strong></p></div><div><ul><li data-line="0">nephrotic-range proteinuria</li><li data-line="1">heart failure with preserved ejection fraction: myocardial wall thickening with low-voltage electrocardiography waveforms<ul><li data-line="2">Tempo of onset (senile is slower)</li><li data-line="3"></li></ul></li><li data-line="4">a gradual decrease in the need for antihypertensive drugs</li><li data-line="5">nondiabetic peripheral neuropathy (ascending, symmetrical with approximately 50% having antecedent carpal tunnel syndrome)</li><li data-line="6">hepatomegaly with alkaline phosphatase elevation</li><li data-line="7">noninfectious chronic diarrhea</li><li data-line="8">erectile or bladder dysfunction</li></ul></div><div><p><span width="475" alt="WhatsApp Image 2023-06-23 at 13.20.35 1.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.20.35-1.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.20.35 1.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.20.35-1.jpg" style="max-width:100%"></span></p></div><div><p></p><div width="500" alt="../_resources/e2b176b5344903f9b8d26b23f14a7e5a.png" src="lib\media\e2b176b5344903f9b8d26b23f14a7e5a.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/e2b176b5344903f9b8d26b23f14a7e5a.png" src="lib\media\e2b176b5344903f9b8d26b23f14a7e5a.png" style="max-width:100%"></div><p></p></div><div><p>Case: 60 presents with fluid overload, diffuse mucocutaneoux bleeding, PT and PTT prolonged/corrects with mixing, factor X level markedly low</p></div><div><ul><li data-line="0">Amyloid fibrils absorb factor X leading to acquired deficiency</li><li data-line="1">Screening: IFE, SPEP, light chain</li><li data-line="2">Troponin, NT pro BNP for cardiac risk stratification</li></ul></div><div><p><strong>DIAGNOSIS</strong></p></div><div><p><span width="475" alt="WhatsApp Image 2023-06-23 at 13.21.44.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.21.44.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.21.44.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.21.44.jpg" style="max-width:100%"></span></p></div><div><p></p><div width="500" alt="../_resources/fccca58da12ef4a64174d1aa710a2b62.png" src="lib\media\fccca58da12ef4a64174d1aa710a2b62.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/fccca58da12ef4a64174d1aa710a2b62.png" src="lib\media\fccca58da12ef4a64174d1aa710a2b62.png" style="max-width:100%"></div><p></p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.25.03.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.25.03.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.25.03.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.25.03.jpg" style="max-width:100%"></span></p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.25.39.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.25.39.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.25.39.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.25.39.jpg" style="max-width:100%"></span></p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.08.40 1.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.40-1.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.08.40 1.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.40-1.jpg" style="max-width:100%"></span></p></div><div><p>Suspect AL amyloidosis: HFpEF, nephrotic syndrome, hepatomegaly, M protein L &gt; K, tissue diagnosis (fat pad &nbsp;biopsy or organ directed biopsy). Risk stratify with troponin, proBNP.</p></div><div><ul><li data-line="0">Transplant eligible: ASCT</li><li data-line="1">Non-eligible: dara+cyborD, goal dFLC &lt; 40 (ideally &lt; 10)</li></ul></div><div><p></p><div width="500" alt="../_resources/ac187c8cdc8becb778ba20e074b1dccc.png" src="lib\media\ac187c8cdc8becb778ba20e074b1dccc.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/ac187c8cdc8becb778ba20e074b1dccc.png" src="lib\media\ac187c8cdc8becb778ba20e074b1dccc.png" style="max-width:100%"></div><p></p></div><div><p><strong>Organ involvement</strong></p></div><div><p><strong>Renal amyloidosis</strong><br></p><div width="475" alt="../_resources/09e3e05e90ed29bba24cee9fded7ef8c.png" src="lib\media\09e3e05e90ed29bba24cee9fded7ef8c.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/09e3e05e90ed29bba24cee9fded7ef8c.png" src="lib\media\09e3e05e90ed29bba24cee9fded7ef8c.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/e44b7ef383ee01dbdfc7ac9491daf1c5.png" src="lib\media\e44b7ef383ee01dbdfc7ac9491daf1c5.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/e44b7ef383ee01dbdfc7ac9491daf1c5.png" src="lib\media\e44b7ef383ee01dbdfc7ac9491daf1c5.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/5dd9df0194c95c5a8eaa037d79ca67d5.png" src="lib\media\5dd9df0194c95c5a8eaa037d79ca67d5.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/5dd9df0194c95c5a8eaa037d79ca67d5.png" src="lib\media\5dd9df0194c95c5a8eaa037d79ca67d5.png" style="max-width:100%"></div><p></p></div><div><p><strong>Approach to AL amyloidosis</strong></p></div><div><p></p><div width="500" alt="../_resources/00f069da4949ca5c1201c9a116b03acb.png" src="lib\media\00f069da4949ca5c1201c9a116b03acb.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/00f069da4949ca5c1201c9a116b03acb.png" src="lib\media\00f069da4949ca5c1201c9a116b03acb.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Maintenance not typically used but can be in select patients</li></ul></div><div><p><strong>Risk stratification</strong></p></div><div><p>Cardiac risk stratification</p></div><div><p></p><div width="500" alt="../_resources/06555165b529e159e682a314d152d328.png" src="lib\media\06555165b529e159e682a314d152d328.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/06555165b529e159e682a314d152d328.png" src="lib\media\06555165b529e159e682a314d152d328.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/968916755357260cb1324a33dfdfcfc2.png" src="lib\media\968916755357260cb1324a33dfdfcfc2.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/968916755357260cb1324a33dfdfcfc2.png" src="lib\media\968916755357260cb1324a33dfdfcfc2.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/cfc722491bfbe3c7079ea7ceb985b461.png" src="lib\media\cfc722491bfbe3c7079ea7ceb985b461.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/cfc722491bfbe3c7079ea7ceb985b461.png" src="lib\media\cfc722491bfbe3c7079ea7ceb985b461.png" style="max-width:100%"></div><p></p></div><div><p>Risk stratification models</p></div><div style="overflow-x:auto"><table><thead><tr><th></th><th></th><th></th></tr></thead><tbody><tr><td>European modification of 2004 Mayo clinic</td><td><div width="425" alt="../_resources/7effebe57c23283ed9aa6e80157b2e81.png" src="lib\media\7effebe57c23283ed9aa6e80157b2e81.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/7effebe57c23283ed9aa6e80157b2e81.png" src="lib\media\7effebe57c23283ed9aa6e80157b2e81.png" style="max-width:100%"></div></td><td>based on NT-proBNP and cardiac troponin (cTn). Troponin I was used in this figure. Cutoffs are 332 ng/L for NT-proBNP and 100, 35, and 54 ng/L for cTnI, cTnT, and high-sensitivity cTnT, respectively. B-type natriuretic peptide can substitute for NT-proBNP in the staging system (cutoff, 81 ng/L). Patients with stage I, II, and III have 0, 1, and 2 markers above the cutoff, respectively. Patients with stage III are classified as stage IIIa or IIIb according to concentration of NT-proBNP below or above 8500 ng/L</td></tr><tr><td>Revised Mayo clinic</td><td><div src="lib\media\2ea2e0936dfd0fcc52bfe0f18f3f504d.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\2ea2e0936dfd0fcc52bfe0f18f3f504d.png"></div></td><td>NT-proBNP, cTn, and dFLC. Cutoffs are 1800 ng/L for NT-proBNP and 25 ng/L for cTnT. Troponin I can substitute for cTnT (cutoff, 70 ng/L)38 and was used in this figure. Patients with stage I, II, III, and IV have 0, 1, 2, and 3 markers above the cutoff, respectively.</td></tr><tr><td>Renal staging</td><td><div src="lib\media\c18f10c9973fc78b1ddb9f285ee36240.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\c18f10c9973fc78b1ddb9f285ee36240.png"></div></td><td>(eGFR) and proteinuria. Cutoffs are 50 mL/ min per 1.73 m2 for eGFR and 5 g/24 h for proteinuria. Patients with stage I, II, and III have 0, 1, and 2 markers above the cutoff, respectively.</td></tr></tbody></table></div><div><p>Bone marrow involvement</p></div><div><p></p><div width="500" alt="../_resources/3b28140f30afec2feaaf983c8d1a26ed.png" src="lib\media\3b28140f30afec2feaaf983c8d1a26ed.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/3b28140f30afec2feaaf983c8d1a26ed.png" src="lib\media\3b28140f30afec2feaaf983c8d1a26ed.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Plasma cell burden = myeloma like -&gt; PFS better in transplant arm</li></ul></div><div><p>Multivariate predictors for survival<br></p><div width="500" alt="../_resources/4e396385318255ae4437d59b55b6de20.png" src="lib\media\4e396385318255ae4437d59b55b6de20.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/4e396385318255ae4437d59b55b6de20.png" src="lib\media\4e396385318255ae4437d59b55b6de20.png" style="max-width:100%"></div><p></p></div><div><p><strong>RESPONSE assessment</strong></p></div><div><p></p><div width="500" alt="../_resources/2c4d2ce83db5d4031c0ad1a1c8c8dceb.png" src="lib\media\2c4d2ce83db5d4031c0ad1a1c8c8dceb.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/2c4d2ce83db5d4031c0ad1a1c8c8dceb.png" src="lib\media\2c4d2ce83db5d4031c0ad1a1c8c8dceb.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">dFLC: difference between involved and uninvolved free light chain</li><li data-line="1">Previously: achieving a hematologic very good partial response was lowering the difference in free light chains to less than 40 mg/L was sufficient; now the goal has shifted to reaching a complete response (difference in free light chains &lt; 10 mg/L)</li></ul></div><div><p>Staging</p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.08.40.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.40.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.08.40.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.08.40.jpg" style="max-width:100%"></span></p></div><div><p><strong>TREATMENT</strong></p></div><div><p></p><div width="500" alt="../_resources/6b6a6057a96e49f2e364fe8db4a134a4.png" src="lib\media\6b6a6057a96e49f2e364fe8db4a134a4.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/6b6a6057a96e49f2e364fe8db4a134a4.png" src="lib\media\6b6a6057a96e49f2e364fe8db4a134a4.png" style="max-width:100%"></div><p></p></div><div><p><strong>Phase III ANDROMEDA </strong>study comparing daratumumab with cyclophosphamide/bortezomib/dexamethasone to cyclo- phosphamide/bortezomib/dexamethasone</p></div><div><ul><li data-line="0">daratumumab resulted in a significant improvement in the overall response rate (92% vs. 77%),&nbsp;doubling of organ responses at 6 months (cardiac response, 42% vs. 22%; renal response, 53% vs. 24%), and a significant improvement in survival free from major organ deterioration or hematologic progression</li><li data-line="1"><div width="500" alt="../_resources/0a8452c35e9fde8ec04b264d3b59f958.png" src="lib\media\0a8452c35e9fde8ec04b264d3b59f958.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/0a8452c35e9fde8ec04b264d3b59f958.png" src="lib\media\0a8452c35e9fde8ec04b264d3b59f958.png" style="max-width:100%"></div></li><li data-line="2"><div src="lib\media\3fefc709142f0328a84cdaa31ec6335c.png" class="internal-embed media-embed image-embed is-loaded"><img src="lib\media\3fefc709142f0328a84cdaa31ec6335c.png"></div></li></ul></div><div><p><strong>TREATMENT ALGORITHM</strong></p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.40.46.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.40.46.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.40.46.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.40.46.jpg" style="max-width:100%"></span></p></div><div><p><span width="500" alt="WhatsApp Image 2023-06-23 at 13.41.26.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.41.26.jpg" class="internal-embed media-embed image-embed is-loaded"><img alt="WhatsApp Image 2023-06-23 at 13.41.26.jpg" src="lib\media\whatsapp-image-2023-06-23-at-13.41.26.jpg" style="max-width:100%"></span></p></div><div><p></p><div width="500" alt="../_resources/ba9a58c87bec4c864bbda26889adafae.png" src="lib\media\ba9a58c87bec4c864bbda26889adafae.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/ba9a58c87bec4c864bbda26889adafae.png" src="lib\media\ba9a58c87bec4c864bbda26889adafae.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/007fae65ad4e5cae782bde94fb0e3adf.png" src="lib\media\007fae65ad4e5cae782bde94fb0e3adf.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/007fae65ad4e5cae782bde94fb0e3adf.png" src="lib\media\007fae65ad4e5cae782bde94fb0e3adf.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/f0a5ace04c11e1eb13c2c1278abc2bf3.png" src="lib\media\f0a5ace04c11e1eb13c2c1278abc2bf3.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/f0a5ace04c11e1eb13c2c1278abc2bf3.png" src="lib\media\f0a5ace04c11e1eb13c2c1278abc2bf3.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/ce957bfaf534901c9275777356a50a7b.png" src="lib\media\ce957bfaf534901c9275777356a50a7b.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/ce957bfaf534901c9275777356a50a7b.png" src="lib\media\ce957bfaf534901c9275777356a50a7b.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">dara-CyBorD: should response after 2 cycles, if do not, change strategy</li></ul></div><div><p></p><div width="500" alt="../_resources/5b2d2f2e7478f1e75198cf6615275b3b.png" src="lib\media\5b2d2f2e7478f1e75198cf6615275b3b.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/5b2d2f2e7478f1e75198cf6615275b3b.png" src="lib\media\5b2d2f2e7478f1e75198cf6615275b3b.png" style="max-width:100%"></div><br><div width="575" alt="../_resources/092f200e258343072eec355e80065dc7.png" src="lib\media\092f200e258343072eec355e80065dc7.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/092f200e258343072eec355e80065dc7.png" src="lib\media\092f200e258343072eec355e80065dc7.png" style="max-width:100%"></div><p></p></div><div><p><strong>Why transplant?</strong></p></div><div><p>TRANSPLANT ELIGIBLE</p></div><div><p></p><div width="500" alt="../_resources/4259f1d0336d7278e450c445d2db3f97.png" src="lib\media\4259f1d0336d7278e450c445d2db3f97.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/4259f1d0336d7278e450c445d2db3f97.png" src="lib\media\4259f1d0336d7278e450c445d2db3f97.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Melphalan dosing based on age and organ involvement</li><li data-line="1">If achieve CR (~33% pts) after ASCT: observation</li><li data-line="2">If do not achieve CR: bortezomib can achieve 60% CR</li><li data-line="3">Caveat: these are transplant eligible patients</li></ul></div><div><p></p><div width="475" alt="../_resources/e5de8e38cec8d36fdce11932b7a620ef.png" src="lib\media\e5de8e38cec8d36fdce11932b7a620ef.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/e5de8e38cec8d36fdce11932b7a620ef.png" src="lib\media\e5de8e38cec8d36fdce11932b7a620ef.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/361c50683aeac2b01cf81d2a213c07d4.png" src="lib\media\361c50683aeac2b01cf81d2a213c07d4.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/361c50683aeac2b01cf81d2a213c07d4.png" src="lib\media\361c50683aeac2b01cf81d2a213c07d4.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">D-VCd higher CR than ASCT</li></ul></div><div><p><strong>Transplant eligibility&nbsp;</strong></p></div><div><p></p><div width="475" alt="../_resources/832b4dbb557726e80ee2d0038f0b1f45.png" src="lib\media\832b4dbb557726e80ee2d0038f0b1f45.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/832b4dbb557726e80ee2d0038f0b1f45.png" src="lib\media\832b4dbb557726e80ee2d0038f0b1f45.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0"><div width="400" alt="../_resources/a62aaa76abdc85dd90393141cb96d85a.png" src="lib\media\a62aaa76abdc85dd90393141cb96d85a.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/a62aaa76abdc85dd90393141cb96d85a.png" src="lib\media\a62aaa76abdc85dd90393141cb96d85a.png" style="max-width:100%"></div></li><li data-line="1">Transplant for those already on dialysis then amyloid</li><li data-line="2">Conditions associated with excess mortality<ul><li data-line="3">3 organ involvement is barrier to transplantation due to excess mortality: volume distribution becomes an issue</li><li data-line="4">Significant cardiac involvement with elevated BNP: high risk of cardiac complications</li><li data-line="5">Liver involvement: risk of VOD following transplant</li><li data-line="6">GI involvement: bleeding with transplant</li></ul></li></ul></div><div><p><strong>Comparing between induction regimens: D-VCd</strong><br></p><div width="500" alt="../_resources/d956c7cbe3c1ab718c498e1c70637e93.png" src="lib\media\d956c7cbe3c1ab718c498e1c70637e93.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/d956c7cbe3c1ab718c498e1c70637e93.png" src="lib\media\d956c7cbe3c1ab718c498e1c70637e93.png" style="max-width:100%"></div><p></p></div><div><p><strong>Outcome after transplant</strong></p></div><div><p></p><div width="500" alt="../_resources/385b52bd1edf780fbf9702966e96ea36.png" src="lib\media\385b52bd1edf780fbf9702966e96ea36.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/385b52bd1edf780fbf9702966e96ea36.png" src="lib\media\385b52bd1edf780fbf9702966e96ea36.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/5b33eb30bcf76ec5b3342969ebb31d8c.png" src="lib\media\5b33eb30bcf76ec5b3342969ebb31d8c.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/5b33eb30bcf76ec5b3342969ebb31d8c.png" src="lib\media\5b33eb30bcf76ec5b3342969ebb31d8c.png" style="max-width:100%"></div><p></p></div><div><p>Melphalan dose</p></div><div><ul><li data-line="0"><div width="500" alt="../_resources/86fb46201948b9450231061359c4eaf7.png" src="lib\media\86fb46201948b9450231061359c4eaf7.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/86fb46201948b9450231061359c4eaf7.png" src="lib\media\86fb46201948b9450231061359c4eaf7.png" style="max-width:100%"></div></li></ul></div><div><p></p><div width="500" alt="../_resources/12e4580b9f7f5259bec3cbc52a9d81c5.png" src="lib\media\12e4580b9f7f5259bec3cbc52a9d81c5.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/12e4580b9f7f5259bec3cbc52a9d81c5.png" src="lib\media\12e4580b9f7f5259bec3cbc52a9d81c5.png" style="max-width:100%"></div><p></p></div><div><p><strong>Organ transplant for AL amyloidosis</strong></p></div><div><p></p><div width="500" alt="../_resources/1ccdfdcba8b2ef3890bf76eed6aebe30.png" src="lib\media\1ccdfdcba8b2ef3890bf76eed6aebe30.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/1ccdfdcba8b2ef3890bf76eed6aebe30.png" src="lib\media\1ccdfdcba8b2ef3890bf76eed6aebe30.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Median time to renal recovery is 9 months</li></ul></div><div><p>Heart transplant: viable if can achieve hematologic response<br></p><div width="500" alt="../_resources/552721f2ffa069c63776c3a8a645e807.png" src="lib\media\552721f2ffa069c63776c3a8a645e807.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/552721f2ffa069c63776c3a8a645e807.png" src="lib\media\552721f2ffa069c63776c3a8a645e807.png" style="max-width:100%"></div><p></p></div><div><p><strong>Transplant ineligible</strong></p></div><div><p><strong>First line therapy</strong></p></div><div><p></p><div width="500" alt="../_resources/c56b422c58ec19feda13973a6e3cf9e0.png" src="lib\media\c56b422c58ec19feda13973a6e3cf9e0.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/c56b422c58ec19feda13973a6e3cf9e0.png" src="lib\media\c56b422c58ec19feda13973a6e3cf9e0.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/e59ebabc7397cee8ea7e4d22387b8f99.png" src="lib\media\e59ebabc7397cee8ea7e4d22387b8f99.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/e59ebabc7397cee8ea7e4d22387b8f99.png" src="lib\media\e59ebabc7397cee8ea7e4d22387b8f99.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Organ response is usually delayed</li></ul></div><div><p></p><div width="500" alt="../_resources/bd5b889b13963073f178a48453f42aaa.png" src="lib\media\bd5b889b13963073f178a48453f42aaa.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/bd5b889b13963073f178a48453f42aaa.png" src="lib\media\bd5b889b13963073f178a48453f42aaa.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/c34a2696aed082b78f89bfd1fd2f5ebb.png" src="lib\media\c34a2696aed082b78f89bfd1fd2f5ebb.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/c34a2696aed082b78f89bfd1fd2f5ebb.png" src="lib\media\c34a2696aed082b78f89bfd1fd2f5ebb.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/2271db9da5947bf735f22b1ffcccbc92.png" src="lib\media\2271db9da5947bf735f22b1ffcccbc92.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/2271db9da5947bf735f22b1ffcccbc92.png" src="lib\media\2271db9da5947bf735f22b1ffcccbc92.png" style="max-width:100%"></div><p></p></div><div><p>Risk adapted<br></p><div width="400" alt="../_resources/eec459d70d52836e06e5e5c1ded52d8e.png" src="lib\media\eec459d70d52836e06e5e5c1ded52d8e.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/eec459d70d52836e06e5e5c1ded52d8e.png" src="lib\media\eec459d70d52836e06e5e5c1ded52d8e.png" style="max-width:100%"></div><p></p></div><div><p>Clone adapted<br></p><div width="500" alt="../_resources/108575c79662dd08cb0907981beb270d.png" src="lib\media\108575c79662dd08cb0907981beb270d.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/108575c79662dd08cb0907981beb270d.png" src="lib\media\108575c79662dd08cb0907981beb270d.png" style="max-width:100%"></div><p></p></div><div><p>Patient adapted<br></p><div width="500" alt="../_resources/5ee6ad8d2bd92c009492771a1505d142.png" src="lib\media\5ee6ad8d2bd92c009492771a1505d142.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/5ee6ad8d2bd92c009492771a1505d142.png" src="lib\media\5ee6ad8d2bd92c009492771a1505d142.png" style="max-width:100%"></div><p></p></div><div><p><strong>Time to response is important</strong></p></div><div><p></p><div width="500" alt="../_resources/871e948140f4d0d28de2f57a6c8284ab.png" src="lib\media\871e948140f4d0d28de2f57a6c8284ab.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/871e948140f4d0d28de2f57a6c8284ab.png" src="lib\media\871e948140f4d0d28de2f57a6c8284ab.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Difference in outcome between 1 month and 3 month hematologic response</li></ul></div><div><p><strong>Consider primary refractory if do not response within 2 cycles</strong><br></p><div width="500" alt="../_resources/1a32958de2ea5e2dd049f7230300d7cd.png" src="lib\media\1a32958de2ea5e2dd049f7230300d7cd.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/1a32958de2ea5e2dd049f7230300d7cd.png" src="lib\media\1a32958de2ea5e2dd049f7230300d7cd.png" style="max-width:100%"></div><p></p></div><div><p><strong>SUPPORTIVE care</strong></p></div><div><p></p><div width="500" alt="../_resources/1c8599638618f8a8ba50624b52af0aa4.png" src="lib\media\1c8599638618f8a8ba50624b52af0aa4.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/1c8599638618f8a8ba50624b52af0aa4.png" src="lib\media\1c8599638618f8a8ba50624b52af0aa4.png" style="max-width:100%"></div><p></p></div><div><p><strong>Relapse</strong></p></div><div><p></p><div width="500" alt="../_resources/ba93464ec99beb4fe2b9e1e5b41c0801.png" src="lib\media\ba93464ec99beb4fe2b9e1e5b41c0801.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/ba93464ec99beb4fe2b9e1e5b41c0801.png" src="lib\media\ba93464ec99beb4fe2b9e1e5b41c0801.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/06b90dce58705e44715e51d5613e0842.png" src="lib\media\06b90dce58705e44715e51d5613e0842.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/06b90dce58705e44715e51d5613e0842.png" src="lib\media\06b90dce58705e44715e51d5613e0842.png" style="max-width:100%"></div><p></p></div><div><p><strong>Therapeutic options&nbsp;</strong></p></div><div><ul><li data-line="0">Re-challenge with cybor-d x 9 cycles</li><li data-line="1">Daratumumab currently not funded in Ontario for amyloid</li></ul></div><div><p></p><div width="500" alt="../_resources/eb0d16e8e57f9fc3b9773fb7a9b63631.png" src="lib\media\eb0d16e8e57f9fc3b9773fb7a9b63631.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/eb0d16e8e57f9fc3b9773fb7a9b63631.png" src="lib\media\eb0d16e8e57f9fc3b9773fb7a9b63631.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/a10736147f8d4c4333a67ed3826ec01d.png" src="lib\media\a10736147f8d4c4333a67ed3826ec01d.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/a10736147f8d4c4333a67ed3826ec01d.png" src="lib\media\a10736147f8d4c4333a67ed3826ec01d.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="500" alt="../_resources/04a435c1f33196ea33cfbe4c91c7ef19.png" src="lib\media\04a435c1f33196ea33cfbe4c91c7ef19.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/04a435c1f33196ea33cfbe4c91c7ef19.png" src="lib\media\04a435c1f33196ea33cfbe4c91c7ef19.png" style="max-width:100%"></div><p></p></div><div><ul><li data-line="0">Hematologic progression occurs months before organ progression: should reinitiate treatment</li></ul></div><div><p></p><div width="500" alt="../_resources/11fefc1c3c36b71484692f6990684b2a.png" src="lib\media\11fefc1c3c36b71484692f6990684b2a.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/11fefc1c3c36b71484692f6990684b2a.png" src="lib\media\11fefc1c3c36b71484692f6990684b2a.png" style="max-width:100%"></div><br>Also light chain stabilizers<p></p></div><div><p>Immunomodulatory agents: lenalidomide - risk of renal dysfunction</p></div><div><p></p><div width="500" alt="../_resources/102b9d4c611e2415ba130f2c59ef887f.png" src="lib\media\102b9d4c611e2415ba130f2c59ef887f.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/102b9d4c611e2415ba130f2c59ef887f.png" src="lib\media\102b9d4c611e2415ba130f2c59ef887f.png" style="max-width:100%"></div><p></p></div><div><p>Daratumumab<br></p><div width="500" alt="../_resources/7a564437f1003d9530e5eddf0594a07e.png" src="lib\media\7a564437f1003d9530e5eddf0594a07e.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/7a564437f1003d9530e5eddf0594a07e.png" src="lib\media\7a564437f1003d9530e5eddf0594a07e.png" style="max-width:100%"></div><p></p></div><div><p>Others</p></div><div><p></p><div width="500" alt="../_resources/228f7cb2a670a5cc33d595595bd7a6fe.png" src="lib\media\228f7cb2a670a5cc33d595595bd7a6fe.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/228f7cb2a670a5cc33d595595bd7a6fe.png" src="lib\media\228f7cb2a670a5cc33d595595bd7a6fe.png" style="max-width:100%"></div><p></p></div><div><p></p><div width="475" alt="../_resources/1806f42776c02127b8de2502131be559.png" src="lib\media\1806f42776c02127b8de2502131be559.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/1806f42776c02127b8de2502131be559.png" src="lib\media\1806f42776c02127b8de2502131be559.png" style="max-width:100%"></div><p></p></div><div><p><strong>Anti-fibrillar antibodies</strong><br></p><div width="500" alt="../_resources/4cffb0aecfccd6af17d54675580b9c8b.png" src="lib\media\4cffb0aecfccd6af17d54675580b9c8b.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/4cffb0aecfccd6af17d54675580b9c8b.png" src="lib\media\4cffb0aecfccd6af17d54675580b9c8b.png" style="max-width:100%"></div><br><div width="500" alt="../_resources/4da639df1ae48d8c1ff4835998d00f5c.png" src="lib\media\4da639df1ae48d8c1ff4835998d00f5c.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/4da639df1ae48d8c1ff4835998d00f5c.png" src="lib\media\4da639df1ae48d8c1ff4835998d00f5c.png" style="max-width:100%"></div><p></p></div><div><p>Summary<br></p><div width="500" alt="../_resources/eaf8c12a7aeaed175ded5f9128dfedc7.png" src="lib\media\eaf8c12a7aeaed175ded5f9128dfedc7.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/eaf8c12a7aeaed175ded5f9128dfedc7.png" src="lib\media\eaf8c12a7aeaed175ded5f9128dfedc7.png" style="max-width:100%"></div><p></p></div><div><p><strong>SUPPORTIVE therapy in AL amyloidosis</strong><br></p><div width="500" alt="../_resources/3e880d3002d4696ec5c276fa69c39e72.png" src="lib\media\3e880d3002d4696ec5c276fa69c39e72.png" class="internal-embed media-embed image-embed is-loaded"><img alt="../_resources/3e880d3002d4696ec5c276fa69c39e72.png" src="lib\media\3e880d3002d4696ec5c276fa69c39e72.png" style="max-width:100%"></div><p></p></div><div class="mod-footer"></div></div></div></div><div class="sidebar-right sidebar"><div class="sidebar-gutter"><div class="clickable-icon sidebar-collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><path d="M21 3H3C1.89543 3 1 3.89543 1 5V19C1 20.1046 1.89543 21 3 21H21C22.1046 21 23 20.1046 23 19V5C23 3.89543 22.1046 3 21 3Z"></path><path d="M10 4V20"></path><path d="M4 7H7"></path><path d="M4 10H7"></path><path d="M4 13H7"></path></svg></div></div><div class="sidebar-container"><div class="sidebar-sizer"><div class="sidebar-content-positioner"><div class="sidebar-content"><div class="graph-view-wrapper"><div class="sidebar-section-header">Interactive Graph</div><div class="graph-view-placeholder"><div class="graph-view-container"><div class="graph-icon graph-expand" role="button" aria-label="Expand" data-tooltip-position="top"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><line x1="7" y1="17" x2="17" y2="7"></line><polyline points="7 7 17 7 17 17"></polyline></svg></div><canvas id="graph-canvas" width="512px" height="512px"></canvas></div></div></div><div class="tree-container outline-tree" data-depth="0"><div class="tree-header"><span class="sidebar-section-header">Table Of Contents</span><button class="clickable-icon collapse-tree-button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></svg></button></div><div class="tree-scroll-area"></div></div></div></div></div></div></div></div></body></html>